Sylvia Guthrie
Psychiatric/Mental Health · Irvine, CANPI 1861146045
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 571 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 571 payments — averaging $24.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Lundbeck LLC$1K
- Neurocrine Biosciences, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$973
- plus $5K from 20 others
What the payments were for
- Food & beverage$14,189100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 120 | $2,646 |
| Johnson & Johnson | 41 | $1,652 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 70 | $1,530 |
| Lundbeck LLC | 58 | $1,178 |
| Neurocrine Biosciences, Inc. | 37 | $1,061 |
| Teva Pharmaceuticals USA, Inc. | 35 | $973 |
| Otsuka America Pharmaceutical, Inc. | 29 | $761 |
| Alkermes, Inc. | 24 | $646 |
| Vanda Pharmaceuticals Inc. | 24 | $615 |
| Ironshore Pharmaceuticals Inc. | 39 | $594 |
| Axsome Therapeutics, Inc. | 16 | $391 |
| Acadia Pharmaceuticals Inc | 5 | $360 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $356 |
| Sunovion Pharmaceuticals Inc. | 6 | $269 |
| Indivior Inc. | 10 | $229 |
| E.r. Squibb & Sons, L.L.C. | 5 | $219 |
| Sage Therapeutics, LLC | 1 | $133 |
| Corium, LLC | 5 | $122 |
| Idorsia Pharmaceuticals US Inc | 7 | $113 |
| Almatica Pharma LLC | 4 | $82 |
| Noven Therapeutics, LLC | 4 | $73 |
| Collegium Pharmaceutical, Inc. | 3 | $62 |
| Bausch Health US, LLC | 3 | $57 |
| Neos Therapeutics, LP | 3 | $50 |
| Sumitomo Pharma America, Inc. | 1 | $9 |
| Brainsway USA Inc | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$722
- VRAYLAR$371
- CAPLYTA$254
- AUSTEDO$242
- REXULTI$241
- INVEGA SUSTENNA$125
- INVEGA TRINZA$125
- COBENFY$120
- NUPLAZID$118
How this compares
$14,189 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $208,031 |
| SpravatoEsketamine Hcl | 29 | $37,480 |
| VraylarCariprazine Hcl | 11 | $21,711 |
| Lurasidone Hcl | 12 | $14,244 |
| TrintellixVortioxetine Hydrobromide | 22 | $10,253 |
| DayvigoLemborexant | 18 | $5,605 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 22 | $1,922 |
| Bupropion XlBupropion Hcl | 84 | $1,652 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 15 | $1,265 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $1,248 |
| Trazodone Hcl | 67 | $724 |
| Aripiprazole | 31 | $613 |
| Mirtazapine | 52 | $607 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 16 | $472 |
| Duloxetine Hcl | 26 | $465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,061 | $208,03117 claims |
| Johnson & JohnsonSpravato | $1,652 | $37,48029 claims |
| AbbVieVraylar | $2,646 | $21,71111 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $356 | $10,25322 claims |
| Almatica Pharma LLCSertraline Hcl | $82 | $29824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Irvine
- Phuong TranIrvine$27K
- Dylan GuineyIrvine$25K
- Jada AlstonIrvine$18K
- Maria AcevedoIrvine$15K
- Salina LumIrvine$15K
- Farhad NikooIrvine$14K
- Kelly EguchiIrvine$12K
- Michelle NguyenIrvine$11K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.